| Date | Title | Description |
| 28.06.2023 | Phaxiam Therapeutics annonce son nouveau code mnémonique sur Euronext et Nasdaq : PHXM | /EIN News/ -- Phaxiam Therapeutics annonce son nouveau code mnémonique
sur Euronext et Nasdaq : PHXM
Lyon (France) et Cambridge (MA, US), 28 juin 2023 – Phaxiam Therapeutics (Nasdaq & Euronext : FR0011471135), annonce la modification du... |
| 28.06.2023 | Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM | /EIN News/ -- Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemon... |
| 23.06.2023 | ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 | /EIN News/ --
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
All resolutions voted with a large majority according to Board of Directors recom... |
| 23.06.2023 | ERYTECH annonce l'approbation de la fusion avec Pherecydes et communique les résultats de l'Assemblée Générale Mixte du 23 juin 2023 | /EIN News/ --
ERYTECH annonce l'approbation de la fusion avec Pherecydes et communique les résultats de l'Assemblée Générale Mixte du 23 juin 2023
Toutes les résolutions ont été votées à une large majorité conformément aux recommandations d... |
| 12.06.2023 | ERYTECH répond à la désinformation d’Akkadian | /EIN News/ -- COMMUNIQUÉ DE PRESSE
ERYTECH répond à la désinformation d’Akkadian
La contestation de la fusion par Akkadian est fondée sur des informations incomplètes et des arguments trompeurs. Akkadian n'a pas présenté d'autre option vala... |
| 12.06.2023 | ERYTECH Responds to Akkadian’s Disinformation | /EIN News/ -- ERYTECH Responds to Akkadian’s Disinformation
Akkadian’s challenge of the merger is based on incomplete information and misleading arguments Akkadian has not presented any valuable alternative option Akkadian’s unfounded actio... |
| 15.05.2023 | ERYTECH Provides Update on the Announced Combination with PHERECYDES | /EIN News/ -- ERYTECH Provides Update on the Announced Combination with PHERECYDES
Entry into a definitive merger agreement between ERYTECH and PHERECYDES Completion of a contribution in kind of PHERECYDES shares to ERYTECH Combination with... |
| 15.05.2023 | Point d'étape sur le rapprochement entre ERYTECH et PHERECYDES | /EIN News/ -- Point d'étape sur le rapprochement
entre ERYTECH et PHERECYDES
Conclusion du traité de fusion entre ERYTECH et PHERECYDES Réalisation d'un apport en nature d'actions PHERECYDES au profit d’ERYTECH Projet de fusion avec PHERECY... |
| 17.04.2023 | ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market | /EIN News/ -- ERYTECH Announces Approval to Transfer its Listing
to the Nasdaq Capital Market
Cambridge, MA (U.S.) and Lyon (France), April 17, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company develop... |
| 17.04.2023 | ERYTECH annonce l'approbation du transfert de sa cotation vers le Nasdaq Capital Market | /EIN News/ -- ERYTECH annonce l'approbation du transfert de sa cotation vers le Nasdaq Capital Market
Cambridge, MA (U.S.) et Lyon (France), 17 avril 2023 – ERYTECH Pharma (Nasdaq & Euronext : ERYP), société biopharmaceutique de stade c... |
| 22.03.2023 | ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 | /EIN News/ -- ERYTECH Provides Business and Financial Update
for the Fourth Quarter and Full Year 2022
Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant ... |
| 22.03.2023 | ERYTECH fait le point sur ses activités et publie ses résultats du quatrième trimestre et de l’année 2022 | /EIN News/ -- ERYTECH fait le point sur ses activités et publie ses résultats du quatrième trimestre et de l’année 2022
Annonce du rapprochement avec Pherecydes dans le but de créer un leader mondial de la phagothérapie étendue ciblant les ... |
| 13.10.2022 | ERYTECH Announces Receipt of Nasdaq Notice | ERYTECH Announces Receipt of Nasdaq Notice
Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therape... |
| 13.10.2022 | ERYTECH Announces Receipt of Nasdaq Notice | ERYTECH Announces Receipt of Nasdaq Notice
Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therape... |
| 13.10.2022 | ERYTECH Announces Receipt of Nasdaq Notice | /EIN News/ -- ERYTECH Announces Receipt of Nasdaq Notice
Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsu... |
| 13.10.2022 | ERYTECH reçoit une notification du Nasdaq | /EIN News/ -- ERYTECH reçoit une notification du Nasdaq
Lyon (France) et Cambridge, MA (U.S), le 13 octobre 2022 – ERYTECH Pharma (Euronext : ERYP ; Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies inn... |
| 12.09.2022 | ERYTECH Provides Business and Financial Update for the First Half of 2022 | ERYTECH Provides Business and Financial Update
for the First Half of 2022
Conference call and webcast on Tuesday, September 13, 2022
at 8:30am ET / 02:30pm CEST
U.S. cell therapy manufacturing facility sold to Catalent in April 2022Evaluati... |
| 24.08.2022 | ERYTECH Provides Regulatory Update | ERYTECH Provides Regulatory Update
ERYTECH to stop further plans to pursue a BLA submission seeking an approval for Graspa® in hypersensitive ALL
Evaluation of strategic partnering options ongoing
Cambridge, MA (U.S.) and Lyon (France), Aug... |
| 24.06.2022 | Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 2022 | REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022
Cambridge, MA (U.S.) and Lyon (France), June 24, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therap... |
| 24.05.2022 | ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 | ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmace... |
| 17.05.2022 | ERYTECH to Present at the H.C. Wainwright Global Investment Conference | ERYTECH to Present at the
H.C. Wainwright Global Investment Conference
Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative the... |
| 12.05.2022 | ERYTECH Provides Business and Financial Update for the First Quarter of 2022 | ERYTECH Provides Business and Financial Update
for the First Quarter of 2022
Conference call and webcast on Friday, May 13, 2022
at 8:30am EDT / 02:30pm CEST
U.S. cell therapy manufacturing facility sold to Catalent for a total consideratio... |
| 28.04.2022 | ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar | ERYTECH Announces Filing of
2021 Universal Registration Document and
2021 Annual Report on Form 20-F,
as well as its 2022 financial calendar
Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (Euronext Paris: ERYP - Nas... |
| 25.04.2022 | ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent | ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent Catalent acquired ERYTECH’s U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 millionERYTECH and Catalent to enter in... |
| 06.04.2022 | ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology | ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL
in the British Journal of Haematology The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option for acute l... |
| 04.04.2022 | ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society | ERYTECH to Present Novel Vesiculation Approach
at the 24th Meeting of the European Red Cell Society Oral presentation detailing the feasibility of producing cargo-loaded extracellular vesicles derived from red blood cells that have been loa... |
| 28.03.2022 | ERYTECH to Participate in the Upcoming April Investor Conferences | ERYTECH to Participate in
the Upcoming April Investor Conferences
Cambridge, MA (U.S.) and Lyon (France), March 28, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therap... |
| 11.03.2022 | ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 | ERYTECH Provides Business and Financial Update
for the Fourth Quarter and Full Year 2021
Conference call and webcast on Tuesday, March 14, 2022
at 8:30am EDT / 1:30pm CET
Progress towards seeking approval of GRASPA® for the treatment of ALL... |
| 08.02.2022 | ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases | ERYTECH Expands Patent Portfolio
for the Treatment of Rare Metabolic Diseases
Cambridge, MA (U.S.) and Lyon (France), February 8, 2022 – ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company develo... |
| 24.01.2022 | ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI | ERYTECH Announces Presentation of
Results of Two Clinical Trials of Eryaspase
in Pancreatic Cancer at ASCO GI Interim results from the Phase 1 rESPECT trial of eryaspase plus mFOLFIRINOX as first-line treatment for advanced pancreatic cance... |
| 03.01.2022 | ERYTECH to Participate in the Upcoming January Virtual Investor Conferences | ERYTECH to Participate in
the Upcoming January Virtual Investor Conferences
Cambridge, MA (U.S.) and Lyon (France), January 3, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innova... |
| 15.12.2021 | ERYTECH ANNOUNCES $7.85 MILLION REGISTERED DIRECT OFFERING | Lyon - ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the 'Company'), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has... |
| 14.12.2021 | ERYTECH Announces $7.85 Million Registered Direct Offering | ERYTECH Announces $7.85 Million
Registered Direct Offering
Lyon (France) and Cambridge, MA (U.S.), December 14, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”), a clinical-stage biopharmaceutical company developing innov... |
| 13.12.2021 | ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI | ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI Full results of the Expanded Access Program in ‘Double Allergic’ acute lymphoblastic leukemia ... |
| 29.11.2021 | ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors | ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatmentNew patent granting a... |
| 15.11.2021 | ERYTECH Provides Business and Financial Update for the Third Quarter of 2021 | ERYTECH Provides Business and Financial Update
for the Third Quarter of 2021
Conference call and webcast on Tuesday, November 16, 2021
at 8:30am EST / 2:30pm CET
Progress towards seeking approval of eryaspase for the treatment of ALL patien... |
| 15.11.2021 | ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting | ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceu... |
| 15.11.2021 | ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting | ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceu... |
| 10.11.2021 | ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal | ERYTECH Announces Publication of a Paper
on Red-Blood Cell Characterization
in High Impact Peer Reviewed Journal
The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation... |
| 10.11.2021 | ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal | ERYTECH Announces Publication of a Paper
on Red-Blood Cell Characterization
in High Impact Peer Reviewed Journal
The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation... |
| 09.11.2021 | ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference | ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
In-Person Dates: November 16th-17th
Virtual Dates: November 18th-19th
Cambridge, MA (U.S.) and Lyon (France), November 9, 2021 – ERYTECH Pharma (Nasdaq &... |
| 25.10.2021 | ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer | ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
Management to host Conference Call on Monday, October 25,
at 8:30am EDT/ 2:30pm CEST
The trial did not meet its prim... |
| 04.10.2021 | ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer | ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of
Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity (DLT) reported in first two dose cohorts, leading to declaration of the maxim... |
| 29.07.2021 | ERYTECH Pharma S A : Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL | ERYTECH Granted U.S. FDA Fast Track Designation
for Eryaspase in Hypersensitive ALL
Fast Track designation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated aspar... |
| 29.04.2021 | ERYTECH Announces $30.0 Million Registered Direct Offering | ERYTECH Announces $30.0 Million
Registered Direct Offering
Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”), a clinical-stage biopharmaceutical company developing innovati... |
| 10.02.2021 | ERYTECH to Present at the 2021 BIO CEO & Investor Conference | ERYTECH to Present at the 2021 BIO CEO &
Investor Conference
Lyon (France) and Cambridge, MA (U.S.), February 10, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative ther... |
| 10.11.2017 | Term Sheet — Friday, November 10 | HOT TAKES
Happy Friday, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Is it too much of a stretch to think we’re going to see tech startups start scooping up traditional publications plagued by de... |
| 07.11.2017 | Term Sheet — Tuesday, November 7 | THE LITTLE PINK PILL
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here’s a quick summary of what happened: Sprout is a Raleigh, N.C.-based developer of a drug intended to treat hypoactive ... |
| 09.10.2017 | Term Sheet — Monday, October 9 | HITTING THE BRAKES
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
The reason? Some large parts of the Model 3 were still being built by hand. This is a pretty big deal as it was not s... |
| 09.10.2017 | Erytech seeks $100M IPO for pivotal tumor starvation trial | Erytech Pharma has filed to raise up to $100 million (€85 million) in a Nasdaq IPO to fund a phase 3 pancreatic cancer trial. The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S.
Lyon, France... |
| 12.09.2017 | Erytech mulls first-line use for pivotal pancreatic cancer trial | Erytech is preparing to move eryaspase into a pivotal trial after full data (PDF) from a phase 2b affirmed earlier top-line results. The red-blood-cell-encapsulated L-asparaginase improved overall survival and other outcomes in metastatic p... |
| 09.12.2015 | Erytech raises €25M to broaden cancer pipeline ahead of possible Nasdaq IPO | Erytech (EPA:ERYP) has raised €25.4 million ($27.4 million) from institutional investors in the U.S. and Europe. The private placement gives Erytech cash to advance its lead tumor starvation drug and move other programs toward and into the ... |
